Important messages from EULAR2021: Impact of air pollution on RA flares, effect of COVID-19 on RA care, osteoporosis care of men

Prof. Giovanni Adami speaks about the most important messages from EULAR 2021.

Which are the most promising new medications in phase 3 clinical trials for the treatment of painful large joint arthritis?

Summarized most promising new medications in phase 3 clinical trials: - Tanezumab - Lorecivivint

What is the role of transdermal fentanyl patches in management of cancer pain?

Dr Mellar Davis insight in pain reduction. The transdermal fentanyl patches changed the way how we treat chronic pain especially in cancer management in the last decades.

Optimising the monitoring and treatment of SSc-ILD

Towards a better understanding of interstitial lung diseases associated with autoimmune rheumatic diseases.

Highlights of the 2019 EASD Congress

David R. Matthews, President of EASD explains the EASD statement on the new guidelines and summarize the highlights of the congress.

DAPA HF : The Dapagliflozin And Prevention Of Adverse‑ outcomes In Heart Failure Trial

The aims of this study were to: (i) report the baseline characteristics of patients enrolled in the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial, (ii) compare DAPA-HF patients to participants in contemporary heart failure (HF) registries and in other recent HF trials, and (iii) compare individuals with diabetes, pre-diabetes and a normal glycated haemoglobin (HbA1c) in DAPA-HF.

Early intervention with oral semaglutide and long term safety

Prof. Melanie Davies speaks about the two torchbearers in cardiovascular protection in diabetes, the SGLT2 inhibitors and GLP-1 analogs.

VERIFY and CONCLUDE study

Prof. Stefano Del Prato summarize the new findings of the VERIFY and CONCLUDE studies.

Cardiorenal risk in type 2 diabetes

Prof. Tina Vilsbøll discusses the current opinion about cardiorenal risk in patients with T2D.

Clinical properties and differences between GLP-1 agonists

Michael A. Nauck speaks about on the combinations of DPP4 inhibitors and SGLT2 inhibitors.

Why We Should Still Care about Glycemic Lowering Strategies for Type 2 Diabetes

Prof. Hertzel Gerstein speaks about the question of the importance of glycemic control in the management of type 2 diabetes.

Diabetic retinopathy: Is the eye a mirror of the brain?

Prof. Coen D. A. Stehouwer speaks about the connection between diabetic retinopathy and other complications of diabetes.

Cardiovascular risk factors

Leading role of hypertension in CV risk scene

Controversial issues in guidelines

Cardiovascular mode of action of GLP-1 receptor agonists

Medical Devices in Diabetes

Will SGLT2-inhibitors change the landscape?

Innate immunity in pancreatic islet inflammation

The artificial beta cell. When will the dream become reality?

Observational study of insulin pump treatment

The evidence for metformin is unclear?

The ORIGIN Study And Legacy Effects

EMPA-REG OUTCOME - a long-term, outcom study of empagliflozin in pateints with T2D at high CV risk

Principal investigator presenting the results of EMPA-REG OUTCOME trial

Mathematic modelling of fibrinolysis

Pre and perioperative factors modulate fibrinolysis in arthroplasty patients

Cellular and mechanical modulators of fibrin structure

Platelets, NETs and Immunity

Mechanisms by which DNA, histones and NETs stabilise clots

Free fatty acids modulate thrombin activity ov fibrinogen and destabilise fibrin clots

Genetics of thrombosis